[Heteroimmune hemolytic anemia associated with antilymphocyte globulin treatment in a patient with aplastic anemia].
Abstract: A 24-year-old male patient with a severe aplastic anemia (SAA) was treated with equine-antilymphocyte globulin (ALG). As complication of this treatment he developed a severe heteroimmune hemolytic anemia mediated by anti-species pan-agglutinin antibodies present in ALG. In spite of the fact that ALG is absorbed with red-cell stroma and platelets to remove anti-erythrocyte and anti-platelet contaminating antibodies, often only partial absorption is achieved, and the remaining antibodies are passively acquired by the recipient. Neutropenia and especially thrombocytopenia are usual complications of this treatment, but it is also possible to detect anti-erythrocyte antibodies in the serum and on the red cells of those patients. However, the unusual severity of the hemolysis suffered by our patient, with a striking decrease of the hemoglobin levels (Fig. 1) can be ascribed to the administration of ALG at a time at which the hematocrit was close to normal as a result of the previous administration of anabolics. It is likely that in severely anemic patients, with a high transfusional demand, such a hemolytic episode may remain undetected. The patient acquired reactivity to the direct antiglobulin test, as well as the positive results of investigation of unexpected antibodies and compatibility testing can be accounted for by the fact that commercial antihuman globulin serum (AGS) contains antibodies reacting with a globulin component shared by human and horse sera. Neutralization of AGS with ALG administered to the patient removed those cross-reacting antibodies, making it possible to perform reliable transfusion compatibility testing and to rule out the eventual presence of hidden alloantibodies or warm autoantibodies. Neutralized Coombs serum maintained its human antiglobulin properties unaltered (Table 1).(ABSTRACT TRUNCATED AT 250 WORDS)
Publication Date: 1990-01-01 PubMed ID: 2130232
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
- Case Reports
- English Abstract
- Journal Article
Summary
This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.
This research article discusses the case study of a 24-year-old male who underwent treatment for severe aplastic anemia (SAA) using equine-antilymphocyte globulin. However, he developed severe heteroimmune hemolytic anemia as a complication linked to this treatment procedure.
Introduction and Case Description
- The study reviews the case of a 24-year-old male patient suffering from severe aplastic anemia, a condition where the body fails to produce enough new blood cells.
- The patient was treated using equine-antilymphocyte globulin (ALG), a common therapy for SAA. However, he developed a severe case of heteroimmune hemolytic anemia as a side effect.
- Heteroimmune hemolytic anemia is a condition where the immune system starts attacking and destroying the red blood cells, leading to anemia.
The Role of Antilymphocyte Globulin (ALG) and Complications
- The research explains that this adverse reaction was likely due to anti-species pan-agglutinin antibodies present in the ALG.
- Despite efforts taken to eliminate contaminating anti-erythrocyte and anti-platelet antibodies from ALG, only partial absorption is achieved, and the patient can acquire the remaining antibodies.
- Typical complications from this treatment include neutropenia and thrombocytopenia. However, anti-erythrocyte antibodies can also be detected in patients and contribute to hemolytic anemia.
Understanding the Severity and Potential Undetected Cases
- The severity of hemolysis in this patient, with significantly decreased hemoglobin levels, was unusual, and seems to be connected with administering the ALG when the patient’s hematocrit was close to normal following earlier anabolic treatment.
- The study suggests that similar episodes of hemolysis might go unnoticed in severely anemic patients with high transfusion demands.
Implications for Testing and Transfusions
- The acquired reactivity to the direct antiglobulin test and the positive results for unexpected antibodies can be attributed to the presence of antibodies reacting with a globulin component shared by human and horse sera in the commercially available antihuman globulin serum (AGS).
- Neutralizing the AGS with the patient-administered ALG removed these cross-reacting antibodies, allowing for reliable transfusion compatibility testing and confirmation of the absence of hidden alloantibodies or warm autoantibodies.
Cite This Article
APA
Goldztein S, Carreras Vescio LA, Salamone HJ, Calahonra R, Kohan AI, Sánchez Avalos JC.
(1990).
[Heteroimmune hemolytic anemia associated with antilymphocyte globulin treatment in a patient with aplastic anemia].
Medicina (B Aires), 50(4), 361-364.
Publication
Researcher Affiliations
- Departamento de Hemoterapia e Inmunohematología, Hospital de Clínicas José de San Martín, Facultad de Medicina, Universidad de Buenos Aires, Argentina.
MeSH Terms
- Adult
- Anemia, Aplastic / therapy
- Anemia, Hemolytic / etiology
- Antilymphocyte Serum / adverse effects
- Antilymphocyte Serum / therapeutic use
- Coombs Test
- Hemolysis
- Humans
- Male
Citations
This article has been cited 0 times.Use Nutrition Calculator
Check if your horse's diet meets their nutrition requirements with our easy-to-use tool Check your horse's diet with our easy-to-use tool
Talk to a Nutritionist
Discuss your horse's feeding plan with our experts over a free phone consultation Discuss your horse's diet over a phone consultation
Submit Diet Evaluation
Get a customized feeding plan for your horse formulated by our equine nutritionists Get a custom feeding plan formulated by our nutritionists
